Cost-effectiveness Analysis of a First-Line Treatment with Cadonilimab Plus Platinum-Based Chemotherapy with or Without Bevacizumab for Persistent, Recurrent, or Metastatic Cervical Cancer in China: COMPASSION-16 Trial.
Journal of pharmaceutical policy and practice（2025）
Key words
Cadonilimab,cervical cancer,cost-effectiveness,partitioned survival model,COMPASSION-16 trial
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined